Steroid Refractory GVHD Clinical Trial
Official title:
PrOspective inteRventional Study Exploring the mIcrobiota recolONization in Steroid-Refractory Graft-versus-Host Disease Patients Receiving MaaT013
The objective of the ORION study is to explore the changes of gut microbiota composition following MaaT013 administration and its impact on the immune system in GVHD patients.
The french regulatory authority ANSM approved in July 2019 the use of MaaT013, a pooled microbiome-based enema formulation, under a formalized named-patient use program in France called "Autorisation Temporaire d'Utilisation - ATU nominative protocolisée - ATUn" or Early Access. The ATUn is indicated to provide a benefit in the treatment of patients with grade III-IV aGVHD: - In case of initial resistance to CS alone or in association or in case of failure to other treaments - In first-line therapy in association with CS in case of steroid-dependance (inability to taper CS dose <0.5 mg/kg/d) - In case of digestive aGvHD with overlap syndrome The objective of the ORION study is to explore the changes of gut microbiota composition following MaaT013 administration and its impact on the immune system in GVHD patients. Blood and stool samples will be collected at each visit which explained why the study is thus categorized as research involving the human person with low risks and constraints clinical trial (RIPH2). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04289103 -
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
|
Phase 3 | |
| Not yet recruiting |
NCT06343792 -
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT04769895 -
MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
|
Phase 3 | |
| Completed |
NCT04926194 -
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
|
Phase 2 | |
| Terminated |
NCT04070781 -
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT05663827 -
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
|
Phase 3 | |
| Terminated |
NCT01485055 -
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
|
Phase 2 | |
| Completed |
NCT05052385 -
ECP Combination Study
|
||
| Available |
NCT04768907 -
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
|